Member Info for Chazzy2

Nice article in the Mail today about the research findings. Although neither Angle nor Parsortix are mentioned it is clear that this is what the article is referring to.

Announcement of a placing and the sp goes up.This has to be a first.

The sp may well go lower in the absence of further news but the fundamentals are sound. The current valuation is £8 million, but Salv has a number of potential blockbuster drugs in the pipeline for clinical trials, hopefully starting this year with Intensity Therapeutic's very promising insitu delivery system. Each drug has the potential to be acquired for over $1 billion by one of the big pharmas, if the clinical data supports it. Above all though Salv has a team consisting of the best in its class in the field of cancer immunotherapy and business brains backing it.

The RNS is actually a very positive one. There is no fundamental reason for the drop as far as progress of Salvarx is concerned. The drop is down to the uncertainties following the referendum which has spooked the markets generally. SALV still offers a fantastic opportunity however to be a part of the $80 billion market for immunotherapy drugs, whilst improving the outcome of millions of cancer patients worldwide.

We could really do with an update soon as RNSs have been a bit thin on the ground lately. SALV has enormous potential but news flow is important to maintain investor interest.

You're not comparing like with like. AGL isn't a drug company. It is a medical device company which has a system which works, so it is significantly derisked compared to drug developers, whose drugs may or may not work. Angle's Parsortix system has enormous market potential, hence the higher valuation is justified.

Yes, really great news. And with the backing of such an important KOL too.

Great to hear from you guys. I knew there were other HZM believers out there!! There are many small mining companies which I believe are at an inflexion point in terms of value uplift at the present time. Commodity prices seem to have bottomed out now and are gradually heading north again. Yes I believe too that we have a good management team, that are delivering on their promises. Looking forward to the revised PFS for the combined assets now.

There are two vital conditions which need to be satisfied before commercial sales can commence. The first is regulatory approval. Yes we have the EU mark, but we need FDA approval also, as further endorsement of the product as well as greater market potential. The second, probably even more important, is robust clinical trial data from the KOLs. As soon as the clinical trials from the ovarian cancer study are complete and assuming they are successful, then Angle can go full steam ahead in commercialising Parsortix into the clinical market in the EU initially. It all takes time but this should be a pivotal year for Angle.

Where is everyone? Am I really the first poster in 2016, posting on March 4th?? Commodity prices are moving back up now and so is Ni. All good news for HZM. I know it's early days still for HZM but the revised PFS should make for good reading. Still very undervalued considering the potential for this company when its starts producing.

Here's a thought for everyone. If the Americans were a lot more pedantic about gun control and a loss less pedantic about FDA approval of life saving technology (i.e Parsortix), there would millions of lives spared from a dreadful disease and fewer deaths from gun crime. Sometimes you get that feeling that their priorities are all wrong.

http://www.infomine.com/investment/metal-prices/nickel/ Nickel LME inventories seem to be running down at quite a rate now as production is slowing amongst the big Ni producers due to falling commodity prices. Low prices don't affect HZM at the moment but falling inventories will eventually cause a rebound in the price, hopefully just as HZM is gearing up towards production. With the combined assets of Araguaia and Glencore, HZM is now so incredibly undervalued.

http://www.proactiveinvestors.co.uk/companies/stocktube/4185/horizonte-minerals-chief-on-game-changing-glencore-deal-4185.html

http://www.angleplc.com/angle-news/research-on-ctdna-for-remission-monitoring-of-breast-cancer-patients/

It does not sound as if the test would detect tumour cells in the blood in the way in which the Parsortix would, but rather the test would enable changes in the persons DNA responsible for the cancer to be monitored. In that respect I would guess that the test could be used in conjunction with the Parsortix system, in a similar way in which the ovarian cancer test using the Parsortix system is used in conjunction with RNA markers to increase the level of sensitivity and specificity.

Yes I appreciate your situation. I think markets will fall quite a bit further over the coming months dragging MYI down further. It's the weakening Chinese economy and its recent currency devaluation which has struck alarm bells, particularly in the US market which is heavily over-bought and seeing substantial falls at present. Maybe sell some of your holdings and buy back in a few months. Just a thought. Good luck anyway!

MYI invests in companies all around the world, and markets globally are falling at present because of falling commodity prices, and a slowing Chinese economy which has such an impact on other major economies. I can see this falling at least another 10% over the next few weeks. Put your money in cash for now and wait for the market to stabilise.

Overall encouraging results. It's a shame the Preliminary licence has been put back about 6 months but it does not change the good progress that is otherwise being made. Nickel prices along with other metals has taken a complete hammering hence the low sp but will recover in time. Still a great investment.

Interim results should be out any day now. Let's hope there's some positive news!

We could really do with an update. No RNS since 10th June. What's going on??